News

Our latest community news, ALLG News Edition 8, is now available! Download a copy to read about our highly successful ALLG ALL09 SUBLIME clinical trial. The final results of the ALL09 SUBLIME trial were presented by Chief Investigator Associate Professor Matthew Greenwood at The European Haematology Association Meeting in Madrid, 13-16 June.

The ALL09 trial was aimed at improving the treatment of adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL). ALL is the most common form of childhood cancer, with over 80% of children cured with chemotherapy. Adolescents and adults with ALL, unfortunately, have worse overall survival outcomes, and ALL09 demonstrated that incorporating a new immunotherapy treatment called blinatumomab into standard therapies for adolescents and young adults with ALL resulted in much higher rates of disease remission and fewer side effects for patients.

Find out more about our ALL09 trial and our full clinical trial portfolio by downloading the ALLG Research Report 2023.

You can also read about our research into Chronic Lymphocyctic Leukaemia (CLL), our research leaders and upcoming international and local trials in this disease.

ALLG innovative research has had a significant impact over the last 50 years, driving improvements in treatments for patients worldwide and accelerating research to potentially find a cure for blood cancers.

Read more about ALLG’s blood cancer research by downloading our ALLG News Edition 8. 

 

ALLG News Edition 8 Insights

Through our ALLG News Edition 8 discover how patients are at the centre of everything we do. Read stories from our Consumer Representative Panel (CRP) who have ‘lived cancer experience’ and the important patient voice they provide to our clinical trial process.

In addition, read about our Chief Investigators, who continue to develop new trial concepts to improve treatment for Chronic Lymphocytic Leukaemia (CLL), including our international collaborations that are bringing cutting-edge treatments to Australia and New Zealand.

Download ALLG News Edition 8 and stay up to date with innovative blood cancer trials and treatments by subscribing to ALLG’s Community Newsletters.

 

ALLG’s Impact – Blood Cancer Treatments

ALLG is Australasia’s only not-for-profit, collaborative blood cancer clinical trial group. Our 1,300+  leading haematologists, scientists, and blood cancer researcher members are dedicated to our case for support – accelerating blood cancer treatments and patient outcomes with the aim of finding a cure.

Our mission is to create better treatments and better lives for patients with the full spectrum of blood cancers, including leukaemia, lymphoma, and myeloma. Conducting leading-edge clinical trials drives research that is vital to improving the quality of life for cancer patients.

Visit ALLG to learn more about our organisation and the many ways you can help support our research.